What the FDA labels say about taking them together
Talquetamab and teclistamab
Talquetamab's FDA label of October 8, 2025 names teclistamab in its boxed warning section, and teclistamab's label names talquetamab too. The talquetamab label: “TECVAYLI and TALVEY REMS TALVEY is available only through a restricted program under a REMS called the TECVAYLI and TALVEY REMS because of the risks of CRS and neurologic toxicity, including ICANS.”
Check it at the source: the talquetamab FDA label on DailyMed (effective October 8, 2025); the teclistamab FDA label on DailyMed (effective March 10, 2026).
What does the talquetamab label say about teclistamab?
Talquetamab label, boxed warningBecause of the risk of CRS and neurologic toxicity, including ICANS, TALVEY is available only through a restricted program called the TECVAYLI and TALVEY Risk Evaluation and Mitigation Strategy (REMS) [see Warnings and Precautions (5.3) ].
Talquetamab label, warnings and precautionsTECVAYLI and TALVEY REMS TALVEY is available only through a restricted program under a REMS called the TECVAYLI and TALVEY REMS because of the risks of CRS and neurologic toxicity, including ICANS [see Warnings and Precautions (5.1 , 5.2) ].
Source: FDA drug label (TALVEY), Janssen Biotech, Inc., effective October 8, 2025 (SPL set 9001355e-003d-4d4e-b4ce-337e0fd14952), via openFDA; the full label on DailyMed
What does the teclistamab label say about talquetamab?
Teclistamab label, boxed warningBecause of the risk of CRS and neurologic toxicity, including ICANS, TECVAYLI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TECVAYLI and TALVEY REMS [see Warnings and Precautions (5.3) ].
Teclistamab label, warnings and precautionsTECVAYLI and TALVEY REMS TECVAYLI is available only through a restricted program under a REMS called the "TECVAYLI and TALVEY REMS" because of the risks of CRS and neurologic toxicity, including ICANS [see Warnings and Precautions (5.1 , 5.2) ].
Source: FDA drug label (TECVAYLI), Janssen Biotech, Inc., effective March 10, 2026 (SPL set 54e0f974-ccee-44ea-9254-40e9883cee1e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Talquetamab | Teclistamab | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Leukemia, lymphoma and myeloma |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once